2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 208-210
Technology and Procedures, Molecular Testing, Treatment Considerations, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Genomics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

35 On-treatment elevations of plasma GRP78/bip, an unfolded protein response marker, is associated with venous thromboembolism in multiple myeloma

Laurent Frenzel, MD, PhD, Neha Korde, MD2, Avi Leader, MD3, Andriy Derkach, PhD4, Brenden Bready, MS5, Simon Mantha, MD, MPH6, Saad Z. Usmani, MD7, Jeffrey Zwicker, MD8
1 MSKCC, New York, New York, United States
2 MSKCC, New York, New York, United States
3 MSKCC, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
4 MSKCC, New York, New York, United States
5 MSKCC, New York, New York, United States
6 MSKCC, New York, New York, United States
7 MSKCC, New York, New York, United States
8 MSKCC, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States

Introduction: Venous thromboembolism (VTE) affects up to 20% of patients with multiple myeloma (MM) and remains a major cause of morbidity,  particularly with immunomodulatory drug (IMiD)–based regimens. Existing clinical risk scores (IMPEDE-VTE, PRISM, SAVED) show limited predictive accuracy, and no validated biological marker identifies patients at risk. The unfolded protein response (UPR) is an adaptive cellular stress response that restores protein homeostasis but, when sustained, promotes a pro-inflammatory state. Recently it was shown to drive cancer-associated thrombosis in pre-clinical models through the release of tissue factor–bearing prothrombotic extracellular vesicles. GRP78/BiP, the principal chaperone and master regulator of the UPR, is measurable in plasma by ELISA. In MM, malignant plasma cells are under constitutive UPR activation driven by their high immunoglobulin production, which is further amplified by proteasome inhibitors (PIs) and IMiDs. As the risk of VTE in MM is amplified by therapy, we sought to evaluate whether on-treatment plasma GRP78/BiP is associated with an increased risk of VTE.

Aim: To evaluate whether pre-treatment or on-treatment plasma GRP78/BiP is associated with VTE in MM.

Methods: We studied patients with MM who had cryopreserved plasma at Memorial Sloan Kettering’s myeloma biobank and complete clinical and VTE data. Most patients received bortezomib-based induction, either without an IMiD (CyBorD, 26%) or with an IMiD (RVd, 54%); overall, 70% received an IMiD, nearly all received bortezomib as the proteasome inhibitor (carfilzomib in 3), and anti-CD38 therapy was rarely used. Plasma GRP78/BiP and D-dimer were measured by ELISA at baseline (before treatment) and on-treatment (samples drawn after cycle 1 day 1 through up to 3 months after treatment completion; median 4.5 months from initiation). VTE events within ±6 months of sampling were identified using natural language processing with hematologist adjudication. GRP78/BiP and D-dimer were compared between patients with and without VTE (Wilcoxon rank-sum test), separately in the baseline- and on-treatment-sample cohorts, and correlated with the IMPEDE-VTE, PRISM and SAVED risk scores (Spearman). Multivariable linear regression assessed the association between GRP78/BiP and VTE, adjusting for age, sex, BMI, and time from treatment initiation and antithrombotic prophylaxis (aspirin, LMWH, or DOAC).

Results: On-treatment plasma for 119 patients (of whom 14 developed VTE) was evaluated. Median age was 61 years, 46% were female, median BMI was 26, and median time from start of therapy to sampling was 4.47 months. Thromboprophylaxis was aspirin in 53 patients (45%), LMWH in 7 (6%), or a DOAC in 2 (2%), while 57 (48%) received no pharmacologic prophylaxis. On-treatment, GRP78/BiP was significantly higher in patients who developed VTE (median 3,383 ng/mL (IQR 1,956–3,665) vs 1,985 ng/mL (1,577–2,610)) ; P=0.010). In a multivariable model adjusting for age, sex, BMI, time from treatment initiation and antithrombotic prophylaxis, higher on-treatment GRP78/BiP was associated with VTE (P=0.051). We also evaluated a subgroup of patients who had baseline plasma samples available (90 patients, 7 later developed VTE). At baseline, GRP78/BiP measurements did not differ between patients with and without VTE (median 2,023 vs 1,604 ng/mL; P=0.3). After adjusting for age, sex, and BMI, difference was of similar magnitude by 860 ng/mL for patients in the VTE group (p=0.062).  On-treatment GRP78/BiP showed a weak positive correlation with the IMPEDE-VTE (Spearman correlation coefficient=0.21; P=0.018) and PRISM (ρ=0.22; P=0.037) scores, suggesting it captures thrombotic risk only partly reflected in current models. In contrast, D-dimer did not differ by VTE status at baseline or on-treatment and was unrelated to prophylaxis.

Conclusion: In this MM cohort, plasma GRP78/BiP measured after the initiation of myeloma-directed therapy was associated with increased risk of VTE independently of antithrombotic prophylaxis, whereas baseline levels and D-dimer were not. These findings suggest that on-treatment GRP78/BiP could inform thrombotic risk not captured by current clinical scores, supporting its evaluation for dynamic, on-therapy risk assessment. Confirmatory studies are warranted.

Laurent Frenzel, MD, PhD: Roche - Honoraria; Sobi - Honoraria; Johnson & johnson - Honoraria; Pfizer - Research Funding; Sobi - Research Funding; CSL Behring - Research Funding; Sobi - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); BioMarin - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); CSL Behring - Consultancy (Includes expert testimony); Johnson & johnson - Consultancy (Includes expert testimony)